Piramal Pharma Q2 & H1 FY27 Results: Revenue Up 28%/23%, EBITDA Soars 72%
Piramal Pharma reported Q2 FY27 revenue of ₹2,617 crore (up 28% YoY) and H1 FY27 revenue of ₹4,887 crore (up 23% YoY). EBITDA surged 72% YoY to ₹385 crore (Q2) and ₹669 crore (H1). The company upgraded its FY27 revenue growth outlook to 19-20% with improved profitability.
The substantial year-on-year growth in revenue and EBITDA, coupled with an upgraded financial outlook, is likely to have a significant positive impact on investor sentiment and the company's stock performance.
The company reported strong double-digit revenue growth and a significant increase in EBITDA, alongside an upgraded financial outlook for the fiscal year. This indicates positive operational and financial performance.
Piramal Pharma Limited announced its standalone and consolidated financial results for the quarter and half-year ended September 30, 2026. The company reported a robust revenue growth of 28% year-on-year (YoY) for Q2FY27 and 23% YoY for H1FY27, reaching ₹2,617 crore and ₹4,887 crore, respectively. EBITDA saw a significant surge of 72% YoY in both periods, amounting to ₹385 crore in Q2FY27 and ₹669 crore in H1FY27. This profitability improvement was driven by strong performance across all three business segments: CDMO, CHG, and PCH, alongside higher capacity utilization, operating leverage, and cost optimization.
The Contract Development and Manufacturing Organization (CDMO) business exhibited broad-based growth, with revenues increasing by 36% YoY in Q2FY27 and 28% YoY in H1FY27, supported by strong order inflows and the addition of 22 new customers. The Complex Hospital Generics (CHG) business grew 32% YoY in Q2FY27 and 24% YoY in H1FY27, bolstered by inhalation anesthesia sales and the integration of Kenalog®. Piramal Consumer Healthcare (PCH) delivered steady growth, with Power Brands growing 21% YoY and e-commerce channels showing a 32% YoY increase in H1FY27.
Based on this strong performance and continued business momentum, Piramal Pharma has upgraded its FY27 outlook, now expecting revenue growth of 19% to 20% with significantly higher profitability. The company also announced an investor earnings conference call scheduled for October 28, 2026, to discuss these results.
What to do with a filing like this
Piramal Pharma Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Piramal Pharma Limited. Read the original for the full detail.